drug · small molecule
ubrogepant
Marketedupdated 3mo agoby $ABBV AbbVie Inc.🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval, with an approval for migraine disorder.
targets
Calcitonin gene-related peptide type 1 receptor
all catalysts(0)
nothing on the calendar yet
Trials studying ubrogepant
- phase3Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- phase3Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- phase1A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
- phase3Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
- phase4Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
- phase4Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies
- phase1Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
- phase3Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Nov 10, 2031
~5.2 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (27)
- Dec 22, 2041method-of-use (U-3677)US 11717515
- Dec 22, 2041method-of-use (U-3786)US 11857542
- Dec 22, 2041method-of-use (U-3992)US 12070450
- Dec 22, 2041method-of-use (U-4122)US 12194030
- Dec 22, 2041method-of-use (U-4213)US 12329750
- Jan 30, 2035formulationUS 10117836
- Jan 30, 2035formulationUS 10117836
- Jan 30, 2035formulationUS 11925709
- Jan 30, 2035formulationUS 11925709
- Jan 30, 2035formulationUS 12168004
- Jan 30, 2035formulationUS 12168004
- Jan 30, 2035formulationUS 12220408
- Jan 30, 2035formulationUS 12220408
- Jan 30, 2035formulationUS 12310953
- Jan 30, 2035formulationUS 12310953
- Jan 30, 2035formulationUS 12458632
- Jan 30, 2035formulationUS 12458632
- Jan 30, 2035formulationUS 12458633
- Jan 30, 2035formulationUS 12458633
- Dec 23, 2033compositionUS 8912210
- Dec 23, 2033compositionUS 8912210
- Jul 19, 2032compositionUS 8754096
- Jul 19, 2032compositionUS 8754096
- Nov 10, 2031compositionUS 9499545
- Nov 10, 2031compositionUS 9499545
- Nov 10, 2031method-of-use (U-2718)US 9833448
- Nov 10, 2031method-of-use (U-2718)US 9833448
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 27m ago
Found something off?
comments(0)
5-min edit window · permanent after that